Veerle Surmont

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Marina Chiara Garassino, Byoung Chul Cho, Joo-Hang Kim et al. · The Lancet Oncology · 2018 · 568 citations · Full text

Medicine, Immunology, Pathology +5

Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial

Corinne Faivre‐Finn, M. Snee, Linda Ashcroft et al. · The Lancet Oncology · 2017 · 548 citations · Full text

Effect of early and systematic integration of palliative care in patients with advanced cancer: a randomised controlled trial

Gaëlle Vanbutsele, Koen Pardon, Simon Van Belle et al. · The Lancet Oncology · 2018 · 449 citations

Palliative Care, Family Medicine, Advanced Cancer +8

The effect of early and systematic integration of palliative care in oncology on quality of life and health care use near the end of life: A randomised controlled trial

Gaëlle Vanbutsele, Simon Van Belle, Veerle Surmont et al. · European Journal of Cancer · 2019 · 130 citations

Palliative Care, Quality Of Life, Family Medicine +10

A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03)

Rabab Gaafar, Veerle Surmont, Giorgio V. Scagliotti et al. · European Journal of Cancer · 2011 · 119 citations

Advanced Nsclc, Oncology, Metronomic Therapy +8